Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
dexamethasone
Pharma
Quince explores options after ph. 3 rare disease flop
Quince’s stock price plummeted more than 90% on the phase 3 failure, and the company now intends to "preserve cash and explore available options."
Angus Liu
Jan 30, 2026 10:44am
FDA blasts Edenbridge over 'misleading' exhibit booth panel
Mar 5, 2025 9:55am
Optifye and DelSiTech partner on controlled-release eye drops
Mar 29, 2022 7:50am
J&J touts Darzalex survival win as Sanofi's Sarclisa draws near
Jun 12, 2021 3:00am
Sanofi's Sarclisa keeps pressure on J&J's Darzalex with new nod
Apr 2, 2021 10:53am
Regeneron, Gilead meds star in Trump's COVID treatment plan
Oct 2, 2020 4:55pm
